All In Biotech

Drug Trial Radar · NCT07914894

A Study of Efficacy and Safety of FXS6837 in Anti-C5 Treated PNH Patients.

A Multicenter, Single-Arm, Open-Label Phase III Clinical Study Evaluating the Efficacy and Safety of FXS6837 Capsules in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Remain Anemic After Previous Stable Use of the C5 Complement Inhibitor

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Jan 26, 2027

Primary completion

May 17, 2028

Study completion Aug 10, 2028

Sponsor

Sponsor type
Industry
First posted
Nov 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an single arm, open label designed phase III study to evaluate the efficacy and safety of oral FXS6837 capsules in PNH patients with residual anemia despite the stable treatment with anti-C5 antibody.

Conditions

  • Paroxysmal Nocturnal Hemoglobinuria

Interventions

  • FXS6837 CapsuleDrug

    FXS6837 capsule will be taken orally for 24 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with hemoglobin (Hb) level ≥ 120 g/L in at least 3 of 4 measurements between Week18 and Week24 in the absence of RBC transfusion (defined as no RBC transfusion after Week2 through Week24)Time frame: 24 weeks from Baseline (Week 18 through Week 24)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • TianJin Medical University General Hospital

    Tianjin, China

  • First Affiliated Hospital of Zhejiang University

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.